However, persistence with therapy is suboptimal and linked to reduced drug effectiveness [5–8]. Prior systematic reviews document that fewer than half
of patients persist with osteoporosis treatment for a full year [5, 9, 10], with estimates ranging between 18% and 78% for bisphosphonates [11, 12]. An underreported finding is that many patients who discontinue bisphosphonate therapy reinitiate treatment after an extended gap [13]. To further explore this issue, we studied all new users of oral bisphosphonates among older adults in Ontario from April 1996 to March 2009. We hypothesized that the majority of patients would discontinue treatment, yet a significant proportion would return to therapy after an extended gap in therapy. We also hypothesized that many patients would experience more than one extended gap in therapy, yet cumulative exposure to oral bisphosphonates PFT�� clinical trial would exceed 1 full year of therapy in most patients. Methods Data sources We used Ontario healthcare Talazoparib cell line utilization (medical and pharmacy) databases to identify, characterize and follow all new users of oral bisphosphonates aged 66 or more years in Ontario since 1996. Ontario medical and pharmacy claims databases are widely used for research purposes, and several studies demonstrate data quality [14–18]. Medicare services are funded through comprehensive universal health insurance for all Canadian residents,
and residents of Ontario aged 65 or more years qualify for pharmacy coverage through the Ontario Drug Benefit (ODB) program [19]. The ODB Formulary has included unrestricted access to cyclical etidronate since many 1996 and alendronate and risedronate since 2007. Study cohort We identified new users of alendronate (5, 10, and 70 mg), cyclical etidronate and risedronate (5 and 35 mg) using ODB program data from April 1, 1996 to March 31, 2009. The first date of bisphosphonate dispensing over the entire study period was considered the index date. To ensure a minimum 1 full year
of pharmacy claims history, we restricted inclusion to those aged 66 years or older at index date. We also excluded patients with Paget’s disease diagnosis and patients with any prescription related to osteoporosis (bisphosphonate, calcitonin, raloxifene, or teriparatide) in the year prior to the index date. For descriptive purposes, we defined age at index, and identified bone mineral density (BMD) testing, and fracture history within 1 year prior to the index date (Appendix 1). BMD testing was identified using billing codes for Dual-Photon Absorptiometry (DPA) prior to 1998 and Dual-energy X-ray Absorptiometry (DXA) from 1998 to 2009. These codes have an estimated sensitivity of 98% and specificity of 93% for identifying BMD testing in Ontario [18]. Fractures were identified using selleck screening library outpatient and inpatient billing claims.